HEALTH IN TECH INC-CLASS A (HIT) Fundamental Analysis & Valuation
NASDAQ:HIT • US42217D1028
Current stock price
1.41 USD
-0.03 (-2.08%)
At close:
1.39 USD
-0.02 (-1.42%)
After Hours:
This HIT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. HIT Profitability Analysis
1.1 Basic Checks
- HIT had positive earnings in the past year.
- HIT had a positive operating cash flow in the past year.
1.2 Ratios
- The Return On Assets of HIT (6.32%) is better than 84.46% of its industry peers.
- The Return On Equity of HIT (8.38%) is worse than 60.81% of its industry peers.
- HIT has a better Return On Invested Capital (5.83%) than 78.38% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for HIT is above the industry average of 9.46%.
- The 3 year average ROIC (12.86%) for HIT is well above the current ROIC(5.83%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.32% | ||
| ROE | 8.38% | ||
| ROIC | 5.83% |
ROA(3y)8.69%
ROA(5y)N/A
ROE(3y)15.98%
ROE(5y)N/A
ROIC(3y)12.86%
ROIC(5y)N/A
1.3 Margins
- HIT has a worse Profit Margin (4.68%) than 67.57% of its industry peers.
- HIT has a worse Operating Margin (4.50%) than 81.76% of its industry peers.
- The Gross Margin of HIT (67.07%) is better than 96.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.5% | ||
| PM (TTM) | 4.68% | ||
| GM | 67.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. HIT Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HIT is creating some value.
- There is no outstanding debt for HIT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- HIT has an Altman-Z score of 11.19. This indicates that HIT is financially healthy and has little risk of bankruptcy at the moment.
- HIT's Altman-Z score of 11.19 is amongst the best of the industry. HIT outperforms 100.00% of its industry peers.
- There is no outstanding debt for HIT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 11.19 |
ROIC/WACC0.65
WACC8.94%
2.3 Liquidity
- A Current Ratio of 2.87 indicates that HIT has no problem at all paying its short term obligations.
- HIT has a Current ratio of 2.87. This is amongst the best in the industry. HIT outperforms 91.22% of its industry peers.
- HIT has a Quick Ratio of 2.87. This indicates that HIT is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of HIT (2.87) is better than 91.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.87 | ||
| Quick Ratio | 2.87 |
3. HIT Growth Analysis
3.1 Past
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%53.08%
3.2 Future
- Based on estimates for the next years, HIT will show a very strong growth in Earnings Per Share. The EPS will grow by 209.76% on average per year.
- Based on estimates for the next years, HIT will show a very strong growth in Revenue. The Revenue will grow by 57.32% on average per year.
EPS Next Y-125.25%
EPS Next 2Y209.76%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.3%
Revenue Next 2Y57.32%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
4. HIT Valuation Analysis
4.1 Price/Earnings Ratio
- HIT is valuated quite expensively with a Price/Earnings ratio of 70.50.
- 83.11% of the companies in the same industry are cheaper than HIT, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 26.21. HIT is valued rather expensively when compared to this.
- HIT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 70.5 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- HIT's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. HIT is more expensive than 68.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 36.8 |
4.3 Compensation for Growth
- HIT's earnings are expected to grow with 209.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y209.76%
EPS Next 3YN/A
5. HIT Dividend Analysis
5.1 Amount
- No dividends for HIT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
HIT Fundamentals: All Metrics, Ratios and Statistics
1.41
-0.03 (-2.08%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)03-25 2026-03-25/amc
Earnings (Next)04-20 2026-04-20
Inst Owners4.79%
Inst Owner Change40.97%
Ins Owners74.38%
Ins Owner Change6.61%
Market Cap80.24M
Revenue(TTM)N/A
Net Income(TTM)1.44M
Analysts80
Price Target4.59 (225.53%)
Short Float %3.95%
Short Ratio1.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.99%
Min EPS beat(2)-0.99%
Max EPS beat(2)-0.99%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.53%
Min Revenue beat(2)15.6%
Max Revenue beat(2)23.46%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 70.5 | ||
| Fwd PE | N/A | ||
| P/S | 2.61 | ||
| P/FCF | N/A | ||
| P/OCF | 37.3 | ||
| P/B | 4.68 | ||
| P/tB | 7.31 | ||
| EV/EBITDA | 36.8 |
EPS(TTM)0.02
EY1.42%
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.04
OCFY2.68%
SpS0.54
BVpS0.3
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.32% | ||
| ROE | 8.38% | ||
| ROCE | 7.89% | ||
| ROIC | 5.83% | ||
| ROICexc | 10.77% | ||
| ROICexgc | 30.87% | ||
| OM | 4.5% | ||
| PM (TTM) | 4.68% | ||
| GM | 67.07% | ||
| FCFM | N/A |
ROA(3y)8.69%
ROA(5y)N/A
ROE(3y)15.98%
ROE(5y)N/A
ROIC(3y)12.86%
ROIC(5y)N/A
ROICexc(3y)19.87%
ROICexc(5y)N/A
ROICexgc(3y)65.42%
ROICexgc(5y)N/A
ROCE(3y)20.71%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 473.62% | ||
| Cap/Sales | 9.65% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 107.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.87 | ||
| Quick Ratio | 2.87 | ||
| Altman-Z | 11.19 |
F-Score5
WACC8.94%
ROIC/WACC0.65
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)10.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-125.25%
EPS Next 2Y209.76%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%53.08%
Revenue Next Year35.3%
Revenue Next 2Y57.32%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-70.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year275.49%
EBIT Next 3Y159.05%
EBIT Next 5YN/A
FCF growth 1Y231.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.34%
OCF growth 3YN/A
OCF growth 5YN/A
HEALTH IN TECH INC-CLASS A / HIT Fundamental Analysis FAQ
What is the ChartMill fundamental rating of HEALTH IN TECH INC-CLASS A (HIT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to HIT.
What is the valuation status of HEALTH IN TECH INC-CLASS A (HIT) stock?
ChartMill assigns a valuation rating of 1 / 10 to HEALTH IN TECH INC-CLASS A (HIT). This can be considered as Overvalued.
Can you provide the profitability details for HEALTH IN TECH INC-CLASS A?
HEALTH IN TECH INC-CLASS A (HIT) has a profitability rating of 4 / 10.
What is the expected EPS growth for HEALTH IN TECH INC-CLASS A (HIT) stock?
The Earnings per Share (EPS) of HEALTH IN TECH INC-CLASS A (HIT) is expected to decline by -125.25% in the next year.
Can you provide the dividend sustainability for HIT stock?
The dividend rating of HEALTH IN TECH INC-CLASS A (HIT) is 0 / 10 and the dividend payout ratio is 0%.